Keon Woo Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keon Woo Kim has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jeong Ho Lee
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea
5 shared publications - Eui Hyun Kim
Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
4 shared publications - Hyun Kim
Department of Anatomy and Brain Korea 21 Graduate Program, Biomedical Science, College of Medicine, Korea University, Seoul, Korea
4 shared publications - Jihwan Yoo
Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, Republic of Korea
4 shared publications - Jong Hee Chang
Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea
4 shared publications - Jung Won Park
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea
4 shared publications
Latest Publications
- Top Cited Papers
- 8 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6781) , eadt0559
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
Identifying the cell of origin that harbors an initial driver mutation is key to understanding tumor evolution and for the development of new treatments. For isocitrate dehydrogenase (IDH)–mutant gliomas, the most common malignant primary brain tumor in young adults, the cell of origin is currently poorly understood. We conducted deep sequencing on 142 tissues from 70 individuals comprising tumors, peritumoral cortex or subventricular zones, and blood. Low-level IDH mutations were found in the peritumoral cortex in 37.9% (11 of 29) of patients. Integrating cell-type–specific mutation analysis, the direction of clonal evolution, spatial transcriptomics from patient brains, and a cancer mouse model arising from mutant oligodendrocyte progenitor cell, we determined that glial progenitor cells harboring an initial IDH mutation were responsible for the development of IDH-mutant gliomas.
- 8 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6781) , eadt0559
Top Cited PapersIDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation
Identifying the cell of origin that harbors an initial driver mutation is key to understanding tumor evolution and for the development of new treatments. For isocitrate dehydrogenase (IDH)–mutant gliomas, the most common malignant primary brain tumor in young adults, the cell of origin is currently poorly understood. We conducted deep sequencing on 142 tissues from 70 individuals comprising tumors, peritumoral cortex or subventricular zones, and blood. Low-level IDH mutations were found in the peritumoral cortex in 37.9% (11 of 29) of patients. Integrating cell-type–specific mutation analysis, the direction of clonal evolution, spatial transcriptomics from patient brains, and a cancer mouse model arising from mutant oligodendrocyte progenitor cell, we determined that glial progenitor cells harboring an initial IDH mutation were responsible for the development of IDH-mutant gliomas.
- 14 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (22) , 4296-4298
White Matter Injury Fuels Early Progression of Glioblastoma
Glioblastoma (GBM) is the most aggressive and devastating primary brain cancer in adults. Most GBMs are diagnosed at an advanced stage with therapy resistance, posing a major obstacle to understanding the tumor microenvironment (TME) at the earliest stages of disease development. A precise characterization of early-stage GBM and its TME could provide critical insights into tumor progression and inform new therapeutic strategies. In a recent issue of Nature, Clements and colleagues demonstrated that white matter (WM) injury, induced by early tumor cells, constitutes a key TME factor driving GBM progression. Using somatic mouse models, patient-derived xenografts, and human tissues, they showed that early glioma cells preferentially infiltrate WM tracts, inducing sterile alpha and TIR motif–containing 1–mediated Wallerian degeneration that propagates into distal WM regions. Remarkably, WM injury induced by axonal transection significantly accelerated GBM progression at distal sites, whereas this effect was abolished by Sarm1 knockout, confirming that axonal injury followed by Wallerian degeneration drives distal tumor progression. Collectively, these findings reveal a previously unrecognized evolutionary process in GBM development and highlight potential targets for therapeutic intervention.
- 14 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (22) , 4296-4298
White Matter Injury Fuels Early Progression of Glioblastoma
Glioblastoma (GBM) is the most aggressive and devastating primary brain cancer in adults. Most GBMs are diagnosed at an advanced stage with therapy resistance, posing a major obstacle to understanding the tumor microenvironment (TME) at the earliest stages of disease development. A precise characterization of early-stage GBM and its TME could provide critical insights into tumor progression and inform new therapeutic strategies. In a recent issue of Nature, Clements and colleagues demonstrated that white matter (WM) injury, induced by early tumor cells, constitutes a key TME factor driving GBM progression. Using somatic mouse models, patient-derived xenografts, and human tissues, they showed that early glioma cells preferentially infiltrate WM tracts, inducing sterile alpha and TIR motif–containing 1–mediated Wallerian degeneration that propagates into distal WM regions. Remarkably, WM injury induced by axonal transection significantly accelerated GBM progression at distal sites, whereas this effect was abolished by Sarm1 knockout, confirming that axonal injury followed by Wallerian degeneration drives distal tumor progression. Collectively, these findings reveal a previously unrecognized evolutionary process in GBM development and highlight potential targets for therapeutic intervention.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM.Significance:We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression.See related commentary by Lee and Suvà, p. 1312
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM.Significance:We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression.See related commentary by Lee and Suvà, p. 1312
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S15 from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Supplementary Figure S1. Enrichment of mutation-harboring cells during GBM evolution in the spontaneous GBM mouse model. Supplementary Figure S2. The quality control and pre-processing of single-cell RNA-seq data. Supplementary Figure S3. Characterization of unknown cell clusters. Supplementary Figure S4. Classification of precancerous and cancer cell clusters with associated gene modules. Supplementary Figure S5. Classification of precancerous and cancer cell clusters using single-cell multiome sequencing. Supplementary Figure S6. Classification of cancer cell clusters using single-cell RNA sequencing. Supplementary Figure S7. Changes in cell-cell interaction analyses between precancer and cancer stages. Supplementary Figure S8. Fluorescent in situ hybridization of precancerous cell markers. Supplementary Figure S9. Proliferation analysis after Gap43 and Ccnd1 siRNA treatment. Supplementary Figure S10. Clinical characteristics of GBM patients. Supplementary Figure S11. Single-cell analysis of SVZ and tumor from each patient. Supplementary Figure S12. Characterization of human cell types and unknown cell population. Supplementary Figure S13. Variant allele frequencies of driver mutations. Supplementary Figure S14. Copy number analysis for Pre-CC and CC in patient #1. Supplementary Figure S15. Copy number analysis for Pre-CC and CC in patient #2.
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S15 from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Supplementary Figure S1. Enrichment of mutation-harboring cells during GBM evolution in the spontaneous GBM mouse model. Supplementary Figure S2. The quality control and pre-processing of single-cell RNA-seq data. Supplementary Figure S3. Characterization of unknown cell clusters. Supplementary Figure S4. Classification of precancerous and cancer cell clusters with associated gene modules. Supplementary Figure S5. Classification of precancerous and cancer cell clusters using single-cell multiome sequencing. Supplementary Figure S6. Classification of cancer cell clusters using single-cell RNA sequencing. Supplementary Figure S7. Changes in cell-cell interaction analyses between precancer and cancer stages. Supplementary Figure S8. Fluorescent in situ hybridization of precancerous cell markers. Supplementary Figure S9. Proliferation analysis after Gap43 and Ccnd1 siRNA treatment. Supplementary Figure S10. Clinical characteristics of GBM patients. Supplementary Figure S11. Single-cell analysis of SVZ and tumor from each patient. Supplementary Figure S12. Characterization of human cell types and unknown cell population. Supplementary Figure S13. Variant allele frequencies of driver mutations. Supplementary Figure S14. Copy number analysis for Pre-CC and CC in patient #1. Supplementary Figure S15. Copy number analysis for Pre-CC and CC in patient #2.
- 16 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (7) , 1377-1391
Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM. Significance: We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression. See related commentary by Lee and Suvà, p. 1312
- 16 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (7) , 1377-1391
Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity
Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM. Significance: We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression. See related commentary by Lee and Suvà, p. 1312
- Open Access
- 1 January 2021
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 17 (4) , 579-581
Rapidly Progressive Parkinsonism and Dementia with No Insomnia due to the PRNP D178N Mutation
Park KW, et al. J Clin Neurol. 2021 Oct;17(4):579-581. https://doi.org/10.3988/jcn.2021.17.4.579
- 1 January 2021
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 17 (4) , 579-581
Open AccessRapidly Progressive Parkinsonism and Dementia with No Insomnia due to the PRNP D178N Mutation
Park KW, et al. J Clin Neurol. 2021 Oct;17(4):579-581. https://doi.org/10.3988/jcn.2021.17.4.579
- Open Access
- 10 June 2020
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 63 (6) , 342-353
Usefulness of carotid ultrasonography and treatment of carotid disease
Carotid stenosis is an important etiology of ischemic stroke. Most of the strokes associated with carotid stenosis are caused by artery-to-artery embolism. The risk of embolism highly depends on the stenosis degree and the vulnerability of the carotid plaque. Carotid ultrasonography is useful for evaluating the characteristics of carotid plaque. This review aims to provide information on performing and interpreting the result of carotid ultrasonography and the treatment of carotid artery disease based on the current guidelines. The degree of stenosis can be measured by the diameter reduction and flow velocity criteria. The risk of embolism is highest when the stenosis degree is around 70% to 80%. A heterogeneous echolucent plaque with an irregular surface or an ulcer shows a high risk of embolism. Appropriate treatment is important for the patients with carotid stenosis. In symptomatic patients, a potent antiplatelet treatment, especially during the acute stage, is beneficial. Patients with asymptomatic stenosis over 50% can also be considered for antiplatelet treatments. The associated risk factors should be managed according to the targets. Medically intractable cases or patients with high risk of embolism may receive carotid endarterectomy or carotid artery stenting depending on the concomitant disease and the degree of carotid stenosis. Considering the safety of ultrasound imaging, treatment may be followed-up by carotid ultrasonography.
- 10 June 2020
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 63 (6) , 342-353
Open AccessUsefulness of carotid ultrasonography and treatment of carotid disease
Carotid stenosis is an important etiology of ischemic stroke. Most of the strokes associated with carotid stenosis are caused by artery-to-artery embolism. The risk of embolism highly depends on the stenosis degree and the vulnerability of the carotid plaque. Carotid ultrasonography is useful for evaluating the characteristics of carotid plaque. This review aims to provide information on performing and interpreting the result of carotid ultrasonography and the treatment of carotid artery disease based on the current guidelines. The degree of stenosis can be measured by the diameter reduction and flow velocity criteria. The risk of embolism is highest when the stenosis degree is around 70% to 80%. A heterogeneous echolucent plaque with an irregular surface or an ulcer shows a high risk of embolism. Appropriate treatment is important for the patients with carotid stenosis. In symptomatic patients, a potent antiplatelet treatment, especially during the acute stage, is beneficial. Patients with asymptomatic stenosis over 50% can also be considered for antiplatelet treatments. The associated risk factors should be managed according to the targets. Medically intractable cases or patients with high risk of embolism may receive carotid endarterectomy or carotid artery stenting depending on the concomitant disease and the degree of carotid stenosis. Considering the safety of ultrasound imaging, treatment may be followed-up by carotid ultrasonography.